In-depth proteomic analysis of proteasome inhibitors bortezomib, carfilzomib and MG132 reveals that mortality factor 4-like 1 (MORF4L1) protein ubiquitylation is negatively impacted
Tanya R. Porras-Yakushi, Justin M. Reitsma, Michael J. Sweredoski, Raymond J. Deshaies, Sonja Hess
Topics & Concepts
CarfilzomibMG132BortezomibProteasome inhibitorProteasomeUbiquitinCancer researchBiologyChemistryCell biologyMultiple myelomaBiochemistryImmunologyGeneUbiquitin and proteasome pathwaysPeptidase Inhibition and AnalysisAutophagy in Disease and Therapy